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Cisplatin and CCNU synergism in spheroid cell subpopulations
R.E. Durand
Medical Biophysics Unit, BC Cancer Research Centre, 601 West 10th Avenue, Vancouver, BC, Canada V5Z IL3.
Summary The cytotoxicity of two antineoplastic drugs, cisplatin and CCNU, was evaluated in Chinese
hamster V79 multicell spheroids using the drugs as single agents or combinations. Cells obtained from
different depths within spheroids 550-750 gm in diameter showed different sensitivities to the two agents; the
external cells of the spheroids were more sensitive than the internal cells to cisplatin, whereas the internal cells
were most effectively killed by CCNU. Combining the two agents produced the expected 'complementary'
activity, and in addition, synergism was observed between the drugs at exposure levels practical for clinical
use. For the combination treatments, both the net pattern of cell killing through the spheroid and the degree
of interaction between the agents (quantified using the combination index method) were a function of the dose
ratio of the two drugs, and of overall treatment intensity. BCNU produced patterns of cell killing similar to
CCNU, but showed little interaction with cisplatin. Our results suggest significant clinical potential in using
CCNU with cisplatin, particularly since CCNU-cisplatin combinations were synergistic even in the cell
subpopulations most resistant to each drug as a single agent.
While the antineoplastic agents cisplatin and CCNU each
have significant therapeutic activity against a variety of ex-
perimental and clinical neoplasms (reviewed by Prestayko et
al., 1979; Schabel et al., 1979; Mitchell & Schein, 1986),
neither drug is generally curative as a single agent in human
disease. Unfortunately, the reasons for this lack of success
are difficult to deduce in the clinical situation; lack of tumour
response is generally ascribed to the emergence of 'drug
resistance', but the exact nature of this resistance can seldom
be ascertained in vivo.
These problems have led to an increased recognition of the
value of tumour model systems for investigating the action
and interaction of antineoplastic agents. We have found the
Chinese hamster V79-171 multicell spheroid system (Suther-
land & Durand, 1976), coupled with cell sorter based selec-
tion techniques for determining cellular clonogenicity (Dur-
and, 1986a), to be particularly useful in this regard. V79
spheroids grow spontaneously from single cells placed in
suspension culture, and develop a morphology similar to that
of many solid tumours (Sutherland & Durand, 1976). The
growth fraction decreases with time (Durand, 1976), concur-
rent with karyotypic instability (Olive et al., 1982). Central
necrosis and hypoxia eventually develop in larger spheroids,
as nutrients and oxygen must diffuse in from the periphery
(Sutherland & Durand, 1976). The system thus represents a
novel, easily manageable model relevant to many types of
solid malignancies.
The fluorescence-activated cell sorting techniques we have
developed permit accurate measurement of the drug response
of cells from known positions in the spheroids; in addition to
drug delivery, the cell cycle status, local microenvironment,
and hypoxia have been found to be of importance in modu-
lating the effects of administered drugs (Durand, 1986b,
1989). With the exception of the anthracyclines, drug delivery
is generally not a problem in these spheroids (Durand, 1989).
In contrast, microenvironmental changes within the spheroid
have been shown to influence sensitivity (or resistance) to
antineoplastic drugs to at least as great a degree as, for
example, the resistance typically reported for the MDR
phenotype (Durand, 1986b).
Since it seems reasonable to expect that similar microen-
vironmental considerations will modulate drug activity in
solid tumours in situ, we have had a particular interest in
evaluating combinations of chemotherapeutic agents which
show different patterns of activity through the spheroid. For
example, a drug which preferentially kills the external (cyc-
ling, well-nourished) cells of the spheroid should be com-
plemented by one which has preferential activity against the
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innermost (non-cycling, oxygen and nutrient depleted) spher-
oid cell subpopulations. In fact, that is exactly the response
seen for the two drugs described in this report: cisplatin and
CCNU.
Preliminary experiments confirmed that this two-drug com-
bination appeared useful in terms of the 'complementary
activity' of the agents. Surprisingly, however, we observed
considerably more cytotoxicity than expected. Since each
drug was principally targeting a different cell subpopulation,
the apparent interaction between the drugs was analysed
according to the 'combination index' methodology described
by Chou and Talalay (1984); we have adopted their ter-
minology throughout this report (see Appendix), and separ-
ately analysed interactions between the drugs in each of the
cell subpopulations recovered from the spheroids. Our results
show significant synergism between cisplatin and CCNU, and
suggest that the combination could have considerable thera-
peutic potential, since increased cell killing can be 'directed'
toward desired subpopulations by changing the ratio of cis-
platin:CCNU (dose ratio) administered.
Materials and methods
Cell line and culture techniques
Chinese hamster V79-171B lung cells were used exclusively in
these studies. The cells were routinely maintained as mono-
layers on plastic Petri dishes with biweekly subcultivation in
Eagle's minimal essential medium supplemented with 10%
fetal calf serum. To initiate spheroid growth, asynchronous
cells were removed from the plastic growth dishes by tryp-
sinisation. Spinner culture flasks (100 ml size) were then
inoculated with 106 cells in 70 ml of medium plus 5% serum
and were stirred at 180 r.p.m.; the gas phase contained 5%
CO2 in air. During the growth of the spheroids, the medium
was first changed at day 3; spheroids were transferred into
250 ml flasks at day 4 or 5, and fed daily thereafter (spent
medium was completely removed and replaced with fresh
medium) as previously described (Sutherland & Durand,
1976). Spheroids were used for the studies reported here after
9-12 days of growth, at which time populations were
550-750lim in diameter, and contained 5-8 x 104 cells
(within each spheroid population, diameters typically varied
with a s.e.m. of < 5%).
Drugs and treatment
Clinical formulations of BCNU and CCNU were used (Lom-
ustine and CeeNu, Bristol Laboratories of Canada, Candiac,
Quebec); the drugs were dissolved in ethanol or DMSO
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respectively immediately prior to each usage at concentra-
tions at least 1,000-fold higher than ultimately required, and
the final concentration was achieved by dilution into the
normal growth medium of flasks typically containing
200-1,000 spheroids. Similarly, an injectable (1 mg ml-')
clinical formulation of cisplatin (Bristol), was diluted directly
into the spheroid growth medium as required. Unless other-
wise noted, all drug exposures were for 2-hour intervals
under normal growth conditions; combination treatments
always involved simultaneous addition and removal of the
drugs. Since these drugs are typically prescribed clinically in
terms of mgm-2, we have expressed drug doses in ftgmI1'
rather than tLM to be more compatible with that convention.
Similarly, drug dose ratios were chosen to encompass a
clinically-achievable range.
Cell sortingprocedures
Flow cytometry (FCM) and fluorescence-activated cell sort-
ing utilised a dual-laser Becton-Dickinson FACS-440 (Moun-
tainview, CA). Spheroids were stained with Hoechst 33342
(Sigma Chemical Co., St Louis, MO) at 2 tLM by dilution of
a 1 mM aqueous solution directly into the drug-containing
flask for the final 20 min of drug exposure. At the end of the
exposure, excess drug and stain were removed by aspiration
of the medium after allowing the spheroids to sediment to
the bottom of a collection tube. After three washes, the
spheroids were reduced to a single-cell suspension by using
0.25% trypsin at 37°C for 10-12 min with continuous agita-
tion. The stained, disaggregated single-cell suspension was
then resuspended in at least three volumes of growth medium
to one of trypsin and maintained at 4°C during the sorting
procedure (typically less than I h).
The primary argon laser was operated at 400 mW and
488 nm with the forward scatter and 900 scatter signals
monitored. The second argon laser was operated at 40 mW
power with the 350-360 nm lines, and the Hoechst emission
monitored through a 449 ± 10 nm bandpass filter. The cell
population was discriminated from debris on the basis of the
forward scatter signal; the resulting signals of stain intensity
and 90° scatter (cell size) were processed through matched
logarithmic amplifiers, and the ratio of these signals used to
generate a 'stain concentration' profile, which was integrated
to establish 10 windows of equal cell numbers (Durand,
1986a,b). The actual number of cells desired per Petri dish,
and the number of replicates were preprogrammed, and the
FACS essentially used as a micromanipulator to deposit the
desired numbers of cells into collection tubes, which were
then poured and rinsed into Petri dishes to determine the
clonogenic fraction (Durand, 1986a).
No cytotoxicity of 2liM Hoechst 33342 alone or in com-
bination with CCNU and/or cisplatin was observed; these
control experiments were performed using sorted cell sub-
populations after treatment with either drug or the combina-
tions at 2-3 levels of cell kill, where Hoechst was added to
the disaggregated cells in escalating concentrations to deter-
mine the level at which additional killing appeared. Hoechst
concentrations >5 pLM were required for additional cell kill-
ing in any of the disaggregated subpopulations; this repre-
sented about 10-fold more stain uptake than in the outer cells
and about 2,000-fold excess for the innermost cells relative to
the typical staining achieved for intact spheroids.
Results
Cisplatin is quite effective as a single agent in V79 spheroids
(Figure 1). However, the decreased survival of the external,
cycling cells seen for cells exposed to the drug in situ in
spheroids (Figure la) was not retained when the same cells
were treated with the drug under monodispersed conditions
(Durand, 1986b). Consequently, the increased survival of the
inner cells apparently does not reflect inherent drug resis-
tance, but rather, decreased drug efficacy due either to poor
penetration of the drug, or to microenvironmental modula-
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Figure I Representative 'toxicity profiles' for 2 h cisplatin ex-
posures for V79 spheroids (a), and the relative sensitivity of
selected cell subpopulations to cisplatin (b). Each curve in a
shows survival for 10 subpopulations of equal proportions of
cells recovered from increasing depths into the spheroid; the
horizontal lines indicate the average survival for unsorted sphe-
roid cells. All curves were obtained with the same starting
spheroid population. In b the sensitivity of the outermost 10% of
the cells (fraction 1, Fl), the innermost 10% (FIO), and a sub-
population recovered from about 40pm into the spheroids (F4) is
plotted relative to the net survival of unsorted spheroid cells, thus
showing the sensitivity differential for the selected subpopulations
to cisplatin. Data were obtained from the 'control' (cisplatin-
alone) curves generated for the subsequent cisplatin + CCNU
studies, and each fraction in b thus includes data points from 18
independent determinations.
tion of drug activity in the more central regions of the
spheroid. Based on recent data where a radiolabelled plati-
num analogue showed no penetration problems (Durand,
1989), we favour the interpretation that the cellular microen-
vironment largely determines cisplatin activity. This is also
consistent with our observation that more cytotoxicity at
high cisplatin doses is always observed in intact spheroids
than in the same cells exposed under disaggregated condi-
tions (Durand, 1986b).
To show more clearly the response differential between the
outermost and innermost cell subpopulations, Figure lb
shows individual data points from the 18 independent 'con-
trol' (cisplatin as a single agent) experiments which accom-
panied the other experiments described in this manuscript. ByCISPLATIN AND CCNU IN SPHEROIDS 949
plotting the ratio of the cell survival in selected fractions to
that of the spheroid as a whole, one can immediately eval-
uate both the magnitude and dose-dependence of the survival
differential throughout the spheroids, and the reproducibility
of that effect. A logarithmic drug dose scale was used in
Figure lb to provide better resolution between data points
for the lower drug doses used in these studies.
A very different response to CCNU was observed as a
function of cell location within the spheroids (Figure 2); the
innermost cells were considerably more sensitive to high con-
centrations of this drug than were the outermost cells. Unlike
cisplatin, however, CCNU activity against cells from spher-
oids was identical irrespective of whether intact spheroids or
disaggregated cells were exposed (Durand, 1986b). Thus, the
differential response is inherent to the cells, and unlike cis-
platin, not related to the intra-spheroid microenvironment.
Figure 2b shows the differential response to CCNU be-
tween the innermost and outermost cell subpopulations, in-
cluding individual determinations from 20 independent 'con-
trol' experiments. Two important features are evident. First,
the survival differential was not only reversed relative to
cisplatin, but was also more pronounced. Second, greater
reproducibility was observed among the experiments; this is
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consistent with the premise that the intra-spheroid environ-
ment is of less consequence for CCNU activity than for
cisplatin, and that different spheroid populations would thus
be less variable in response. A third point arises from com-
parison of Figures 2a and 2b; although the spheroids used
throughout these studies were within a size range of
550-750 lm diameter, this range nonetheless resulted in a
non-constant thickness of the viable rim of cells, and conse-
quently given subpopulations of cells were recovered from
different depths for different spheroid populations (Figure
2a). Since the dominant factor appears to be the relative
proximity of a cell to either the spheroid surface or the
necrotic region, rather than absolute distance from the sur-
face per se, we have chosen to intercompare results from
different spheroid populations by always sorting 10 fractions
and grouping on the basis of the fraction number. The con-
sistency of the data in Figure 2b argues favourably for this
approach.
Combination treatments with CCNU and cisplatin (Figure
3) produced the desired result of more uniform cell killing
throughout the spheroid than achievable with equitoxic ex-
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Figure 2 Representative 'toxicity profiles' for 2 h CCNU ex-
posures for V79 spheroids (a) and the relative sensitivity of
selected cell subpopulations to CCNU (b). All data are plotted in
a similar manner to Figure 1 with the exception that different
spheroid populations were analysed in a; in b data from 20
independent determinations are included. Note that the toxicity
differential is reversed for CCNU relative to cisplatin.
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Figure 3 Curves from representative experiments showing sur-
vival of cells sorted from V79 spheroids after exposure to cis-
platin, CCNU, or the combination at low (0.25gtg ml-' cisplatin,
0.125 igml-' CCNU, a) and higher dose intensities (1.0lsgml-I
cisplatin, 0.51gg ml-' CCNU, b). The curves without symbols
show the expected survival fraction by fraction for no interaction
between the drugs (the product of the cisplatin and CCNU
survival values); the much lower observed survivals for both low
and high-dose combinations are suggestive of synergy between
the agents.950 R.E. DURAND
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Figure 4 Comparison of the response of the outermost 10% of
cells from V79 spheroids exposed to single-agent cisplatin, single-
agent CCNU, or the combination at a 1:1 dose ratio (plotted
versus the arithmetic sum of the drug doses). This representation
approximates a dose response, showing effect (cytotoxicity, where
S = surviving fraction) as a function of dose, indicating that
CCNU was the more potent agent, and that the combination
exhibited drug interaction (increased slope). From data trans-
formed and plotted in this manner (see Appendix), the combina-
tion index for each treatment combination and each cell sub-
population was calculated as shown in Figure 5. For further
reference, the dotted lines show the 'envelope of additivity' for
isobologram analysis (see text).
posures to either agent alone. Surprisingly, much more cell
killing was observed than expected based on the product of
surviving fractions for exposures to each drug as a single
agent; this was true for both low (Figure 3a) and high
intensity (Figure 3b) treatments. Perhaps of most signifi-
cance, the apparent interaction between the drugs was ob-
served for all cell subpopulations within the spheroids.
More rigorous quantisation of the effects of the two-agent
treatments is possible using the 'isobologram' analysis (Steel
& Peckham, 1979) or the 'combination index' analysis (Chou
& Talalay, 1984). Although the former is arguably more
rigorous, the latter has a number of practical advantages
(particularly for data display) and consequently was adopted
for this report (see Appendix).
Unambiguous conclusions from the combination index
model require both a reasonable fit of the experimental data
to the median effect equation, and parallelism of the dose-
response curves for the single agents when the data are fit to
that model (Chou & Talalay, 1984). Examples with our data
are shown in Figure 4, where the outermost 10% of the cells
were analysed after exposure to..cisplatin, CCNU, and the
1:1 combination. The increased slope of the latter curve is
indicative of nonexclusive interaction of the agents. It is also
immediately evident by the combination index analysis cri-
teria that the combination was interacting synergistically,
since Figure 4 shows effect (inverse survival) as a function of
dose, and the combination treatment data (hexagons) lie well
above the cisplatin curve at all doses, and above the CCNU
curve at high doses. For intercomparison with the Isobolo-
gram analysis, we have also shown the calculated 'envelope
of additivity' (terminology as in Steel & Peckham, 1979)
based on the survival curves defined for cisplatin and CCNU
in Figure 4; with only one exception, the data for the com-
bination treatments are above that region again indicating
supra-additivity. Experimental reproducibility can be easily
assessed once more, since each data point represents either
the mean or individual survival estimate for every dose
evaluated in the independent experiments.
Figure 4 also illustrates both the magnitude of the interac-
tion between these drugs and the difficulties in designing
experiments to quantify high degrees of synergism. The
highest combination dosage shown was 1.75 fig ml1' cisplatin
plus 1.75 pg ml-' CCNU; it produced more than 3 logs of
cell kill throughout the spheroids. In contrast, even 3.0 ;Lg
ml1l cisplatin as a single agent produced only about 1 log of
kill (as can be derived from Figure 4 or seen in Figure la).
One thus requires analytical techniques which can simul-
taneously resolve small differences at high survival levels (for
single-agent 'control' curves), yet provide data for the very
potent combination treatments.
Our approach was to determine the median effect relation-
ship for a range ofdrug combinations for each of the ten cell
subpopulations collected from spheroids. From these data
(some 330 individual measurements of cytotoxicity for two-
drug treatments) the combination index was calculated as a
function of administered dose fraction by fraction through
the spheroids for several combinations at differing drug dose
ratios. The results are shown in Figure 5, where the figures
on the right relate CI to drug exposure (for ease of intercom-
parison, expressed in terms of the amount of cisplatin in the
combination) and cellular position within the spheroid. These
figures were constructed from 11, 9 and 13 separate treat-
ment doses for the 1:1, 2:1 and 4:1 cisplatin:CCNU drug
ratios respectively. In all cases, synergism (CI < 1.0) was
observed at high drug levels; the net survival produced is
shown as a function of position and drug dose in the left
panels. Cytotoxicity toward the innermost cells became great-
er as the relative CCNU dose increased in the combinations,
and even modest CCNU levels produced significant synergy
within all cell subpopulations for high intensity treatments.
We find it interesting that the interaction seen between
CCNU and cisplatin in this system is qualitatively repro-
duced for BCNU and cisplatin, but quantitatively is greatly
diminished. The experiment showing the largest 'interaction'
we have seen is shown in Figure 6, where the response of cell
subpopulations of the V79 spheroids to 1 h treatments with
BCNU, cisplatin, or the combination was compared to the
expected (independent action) cell kill from the two agents.
The observed cytotoxicity of the combination treatments at
either low (Figure 6a) or high intensity (Figure 6b) was only
slightly greater than the expected response, suggesting that
the modest differences in structure between BCNU and
CCNU result in small differences in activity as single agents
in this system, but produce a considerable difference in com-
bination regimens (compare Figure 6 with Figure 3, where a
dose ratio of 2:1 cisplatin:nitrosourea was used in each case,
and comparable levels of cytotoxicity were produced).
Discussion
The data presented in this report indicate that CCNU and
cisplatin can be synergistic in V79 spheroids. Perhaps more
importantly, the agents, at appropriate concentrations, were
synergistic in all cell subpopulations of the spheroids. Our
intent in the initial phase of this study was to simply deter-
mine whether the complementary cytotoxicity patterns of the
two agents throughout the spheroids would be maintained in
a multi-agent exposure (i.e. were the microenvironmental
factors responsible for differential platinum activity main-
tained even in a perturbed system?). Clearly, the data indicate
that these differences were indeed maintained.
The degree of synergism demonstrated by these two agents
was not expected, and probably would have been discovered
only by chance had we not been selecting drug combinations
based on cell sorting studies of complementary cytotoxicity.
Synergy is not specific to spheroids; we have seen similar
levels for cisplatin and CCNU treatments of monolayer and
suspension cultures of single cells (data not shown). How-
ever, the observed synergism in all subpopulations of cells in
spheroids provides a compelling argument to consider this
drug combination for clinical regimens. 'Non-cross-resis-
tance' of drugs is an established clinical principle for com-
bination chemotherapy; if microenvironmental resistance is
included in that definition, then agents like cisplatin and
CCNU, which have different normal tissue toxicities as well
as different cytotoxicity profiles, emerge as being of potential
utility in combination.
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Figure 5 Response surfaces showing cell survival (left panels), or cisplatin/CCNU interaction (right panels), as a function of
position in spheroid and drug exposure. For ease of comparison, only the cisplatin dose is shown on the panel scales; note that in
the upper panels, 2 fig ml-' cisplatin corresponds to 2 fig ml-' cisplatin + 2 jig ml- CCNU whereas in the lower panels, a slightly
lower total dose of 2 Igml-' cisplatin+0.5figmlm1 CCNU was administered. CI approximates the reduction in total dose
necessary to achieve a given endpoint, thus indicating a strong interaction between cisplatin and CCNU at higher dose levels. As
indicated in the Appendix, CI values at low treatment intensity tend to overestimate antagonism; for clarity, the response surfaces
have consequently been constrained to values of 1.0 or less. The top panels were generated for drug doses ranging from
0.25 jig ml-' cisplatin + 0.25 fig ml- I CCNU to 1.75 fig ml-' cisplatin + 1.75 jg ml-' CCNU; the middle panels for 0.25 fig ml
cisplatin + 0.125 jig ml-' CCNU to 2.0fig ml' cisplatin + 1.0 jgml-I CCNU, and the lower panels for 0.4 jig ml cisplat-
in + 0.1Ilg ml ' CCNU to 3.2 jgml-' cisplatin + 0.8 jig ml-' CCNU (nine of the 13 doses evaluated were within the 0-2 jg ml1
cisplatin range shown on the plot).
It must be remembered that the cells differentially resistant
to cisplatin in the interior of the spheroid, or those more
resistant to CCNU near the exterior of the spheroid, are
likely to be different from 'genetically' resistant cells that
appear during multiple courses of treatment. This point is of
relevance in view of the known 06-methylguanine-DNA
methyltransferase resistance phenotype seen in many human
cell lines in response to nitrosoureas (the Mer+ phenotype,
see Day et al., 1980, 1987). Unlike most human cells, the
Chinese hamster cell lines used in these studies are quite
sensitive to nitrosoureas. In the clinical situation, as well, it
must be noted that the Mer+ or Mer- phenotype may be of
less relevance than whether a relative difference in resistance
of tumour and normal cells is present (Day et al., 1987).
Preliminary experiments in our laboratory with a human
colon carcinoma cell line (WiDR) grown as spheroids have
indicated a synergistic interaction between cisplatin and
CCNU, despite resistance to CCNU in those cells. One might
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Figure 6 Curves from representative experiments showing sur-
vival of cells sorted from V79 spheroids after a I h exposure to
cisplatin, BCNU, or the combination at low (2.0 pg ml- cispla-
tin, 1.0 pg ml- BCNU, a) and high dose intensities (6.0 pg ml-'
cisplatin, 3.0 pg ml-' BCNU, b). The curves without symbols
show the expected survival fraction by fraction for no interaction
between the drugs (product of the cisplatin and BCNU survivals);
the similarity of the observed and expected survivals for both low
and high-dose combinations are suggestive of little interaction
between the agents (particularly in relation to Figure 3).
hope, as well, that an analogy between the current demon-
stration of synergism between cisplatin and CCNU might
parallel the recent report (Mulcahy et al., 1988) that Mer+
resistance can be overcome by using the synergistic combina-
tion of CCNU and mild hyperthermia.
We do not, at present, have an explanation for the lack (or
at least, marked decrease) of synergism between BCNU and
cisplatin. This is not, however, the only difference noted
between BCNU and CCNU in this system. Another example
is the duration of drug exposure; prolonging BCNU exposure
beyond 30 min produces little additional cytotoxicity in sphe-
roids. In contrast, CCNU cytotoxicity increases with increas-
ing exposure times for at least the first 12 h of exposure (as
does cisplatin cytotoxicity; data not shown). Since our intent
in these experiments was to evaluate the synergistic activity
of 'simultaneous' drug exposures, we limited the total expo-
sure time to 1 h for the BCNU/cisplatin combinations.
Two additional features should also be noted. The role of
hypoxic cells is receiving increased attention in clinical chem-
otherapy due to potential problems of the microenvironment
(Sutherland, 1988), lack of drug delivery (Nederman et al.,
1981; Durand, 1989), and perhaps inherent resistance of
those noncycling cells (due in part to potential stimulation/
overexpression of 'resistance genes' by transient hypoxia, e.g.
Rice et al., 1986; Young et al., 1988). One of the more
topical methods to combat this feared resistance is the use of
'bioreductive' drugs which are activated in a hypoxic envir-
onment and thus preferentially toxic to hypoxic cells (Ken-
nedy et al., 1981). We have evaluated a number of such
agents in the spheroids; it is of considerable interest to us
that none of these agents (with the possible exception of
porfiromycin. a mitomycin C analogue) shows any more
preferential activity against the innermost cells of the spher-
oids than either BCNU or CCNU. This also leads us to
speculate that the 'lack' of clinical activity of the nitrosoureas
may in fact be linked to their propensity for killing quiescent,
non-proliferating cells of solid tumours - activity that may
not be easily appreciated in the clinical situation where
regression (or regrowth) is typically the only parameter that
can be quantified. However, the demonstration of preferen-
tial killing of hypoxic/quiescent cells by CCNU, a well estab-
lished, clinically useful agent may provide an additional
opportunity for design of combination chemotherapy pro-
tocols, particularly since cell subpopulations differentially
sensitive to CCNU may be those resistant to cisplatin.
Appendix: analysis of interactions
As previously stated, we have used the analytical procedures devel-
oped by Chou and Talalay (1984), where survival (S) is related to
dose (D) according to the 'median-effect' equation:
(I -S)/S = (D/Dm)m
where m is the sigmoidicity of the curve, and Dm the median dose
(which produces 50% survival).
A log transform of the equation simplifies solution for the con-
stants; resulting parallel curves indicate that the treatment agents can
be added by dose, and the dose giving survival S is then:
D = Dm[(l - S)/SV'1m
The fractional effect (f1) due to drug I in a two-drug scheme then
varies with its concentration (C,):
fl = C/(CI + C2)
Thus, the 'combination index' (CI) can be defined:
(D12) (fl) (D12) (f2) (D12) (fi) (D12) (f2) CTI= +r +
DI D2 (D1) (D2)
where the last term is required only if the agents are non-exclusive
(m is greater for the combined treatment than for either single agent
as observed for all data presented here and shown in Figure 4). In
essence, the combination index CI is the ratio of the combination
dose to the sum of the (isoeffective) single-agent doses; consequently,
CI < 1 shows potentiation (synergism) and CI> I indicates antago-
nism (protection).
The combination index has a number of advantages, and some
disadvantages (e.g. Durand & Goldie, 1987). On the positive side, it
allows a numeric estimation of the degree of agent interaction, and,
as indicated by the last equation above, immediately expresses the
degree of interaction as a function of the level of toxicity produced
(within the limitation, of course, that the two agents must be
administered at a fixed dose ratio). As shown in Figure 5, it is thus
possible to simultaneously relate the amount of interaction, the
administered drug dose, and cellular position in the spheroid. Func-
tionally, this was performed by generating the median-effect plots
fraction by fraction through the spheroid for each drug dose ratio,
then interpolating between fractions by using a polynomial fitting
routine. From Figures la, 2a, 3 and 6 it should be obvious that
subpopulations of cells were located at different depths in spheroids
of different sizes; we consequently expressed position in terms of the
fraction number rather than depth.
On the negative side, the combination index analysis requires that
the data are adequately described by the median effect equation.
While this can generally be achieved over a limited range of doses,
there is necessarily some uncertainty introduced by extrapolationCISPLATIN AND CCNU IN SPHEROIDS 953
beyond the actual ranges of observation. This is perhaps best illus-
trated by comparison of Figure 5, where antagonism is suggested at
low doses, with Figure 3a, which clearly shows strong synergy even
for very modest levels of cell killing. The discrepancy, as shown in
Figure 4, is that the best-fit line for combinations, if increased in
slope, necessarily extrapolates below either single-agent curve at low
doses (a concave upward curve is suggested by the actual data).
However, this problem is of less significance when considered with
the perspective that the combination index analysis produces a quite
conservative estimate of synergism: low dose antagonism is overes-
timated by using the linear best-fit, and high dose synergism is, for
the same reason, underestimated.
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